Patients and transplant characteristics, according to stem cell source
| . | BM . | PB . | CB (children only) . | ||
|---|---|---|---|---|---|
| Children . | Adults . | Children . | Adults . | ||
| N | 728 | 111 | 30 | 43 | 88 |
| Median follow-up, months (range) | 57.8 (0.3-325.4) | 48.46 (2.65-306.67) | 51.0 (1.1-227.9) | 47.88 (2.19-168.4) | 54.2 (3.7-161.9) |
| Median age, years (range) [IQR] | 8.4 (0.3-16) [5.8-11.8] | 18.5 (16-46.2) [16.8-23.3] | 12.7 (2.2-15.9) [9.9-14.6] | 23.4 (17.3-54.4) [19.8-30.1] | 6.1 (1.9-15.5) [4.1-8.5] |
| Median year of Tx (range) [IQR] | 2007 (1986-2013) [2001-2010] | 2008 (1989-2013) [2003-2010] | 2003 (1999-2011) [2001-2008] | 2008 (1997-2012) [2003-2011] | 2009 (1994-2012) [2004-2011] |
| Registry, n (%) | |||||
| EBMT | 400 (55.0) | 54 (48.7) | 19 (63.3) | 17 (39.5) | 71 (80.7) |
| CIBMTR | 328 (45.0) | 57 (51.4) | 11 (36.7) | 26 (60.5) | 17 (19.3) |
| Conditioning type, n (%) | |||||
| MAC | 653 (89.7) | 89 (80.9) | 23 (79.3) | 24 (55.8) | 84 (95.5) |
| RIC | 75 (10.3) | 21 (19.1) | 6 (20.7) | 19 (44.2) | 4 (4.6) |
| GVHD prophylaxis, n (%) | |||||
| CsA | 102 (14.9) | 13 (12.0) | 6 (27.3) | 5 (12.5) | 56 (64.4) |
| CsA+MTX | 447 (65.2) | 57 (52.8) | 9 (40.9) | 5 (12.5) | 16 (18.4) |
| CsA+MMF | 41 (5.9) | 17 (15.7) | 2 (9.1) | 2 (5.0) | 9 (10.3) |
| FK506+/−other | 82 (12.0) | 17 (15.7) | 3 (13.6) | 4 (10.0) | 4 (4.6) |
| Other | 14 (2.0) | 4 (3.7) | 2 (9.1) | 24 (60.0) | 2 (2.3) |
| . | BM . | PB . | CB (children only) . | ||
|---|---|---|---|---|---|
| Children . | Adults . | Children . | Adults . | ||
| N | 728 | 111 | 30 | 43 | 88 |
| Median follow-up, months (range) | 57.8 (0.3-325.4) | 48.46 (2.65-306.67) | 51.0 (1.1-227.9) | 47.88 (2.19-168.4) | 54.2 (3.7-161.9) |
| Median age, years (range) [IQR] | 8.4 (0.3-16) [5.8-11.8] | 18.5 (16-46.2) [16.8-23.3] | 12.7 (2.2-15.9) [9.9-14.6] | 23.4 (17.3-54.4) [19.8-30.1] | 6.1 (1.9-15.5) [4.1-8.5] |
| Median year of Tx (range) [IQR] | 2007 (1986-2013) [2001-2010] | 2008 (1989-2013) [2003-2010] | 2003 (1999-2011) [2001-2008] | 2008 (1997-2012) [2003-2011] | 2009 (1994-2012) [2004-2011] |
| Registry, n (%) | |||||
| EBMT | 400 (55.0) | 54 (48.7) | 19 (63.3) | 17 (39.5) | 71 (80.7) |
| CIBMTR | 328 (45.0) | 57 (51.4) | 11 (36.7) | 26 (60.5) | 17 (19.3) |
| Conditioning type, n (%) | |||||
| MAC | 653 (89.7) | 89 (80.9) | 23 (79.3) | 24 (55.8) | 84 (95.5) |
| RIC | 75 (10.3) | 21 (19.1) | 6 (20.7) | 19 (44.2) | 4 (4.6) |
| GVHD prophylaxis, n (%) | |||||
| CsA | 102 (14.9) | 13 (12.0) | 6 (27.3) | 5 (12.5) | 56 (64.4) |
| CsA+MTX | 447 (65.2) | 57 (52.8) | 9 (40.9) | 5 (12.5) | 16 (18.4) |
| CsA+MMF | 41 (5.9) | 17 (15.7) | 2 (9.1) | 2 (5.0) | 9 (10.3) |
| FK506+/−other | 82 (12.0) | 17 (15.7) | 3 (13.6) | 4 (10.0) | 4 (4.6) |
| Other | 14 (2.0) | 4 (3.7) | 2 (9.1) | 24 (60.0) | 2 (2.3) |
Tx, transplant.